News center

Feb 14, 2019

Miami Cancer Institute adopts Philips IntelliSpace Precision Medicine Genomics

  • Miami Cancer Institute, part of Baptist Health South Florida, implements Philips’ cloud-based comprehensive genomics platform to inform cancer treatment options through advanced diagnostic testing (next generation sequencing) to extend the reach of personalized oncology care  
  • Alliance with Philips enables new genomics lab at Miami Cancer Institute to accelerate the launch of TST170 NGS testing service

Amsterdam, the Netherlands and Miami, Florida Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Miami Cancer Institute, part of Baptist Health South Florida, today announced the implementation of Philips’ IntelliSpace Precision Medicine Genomics in its new state-of-the-art genomics laboratory. The multi-year agreement will power a new initiative to help inform clinical treatment decisions and provide visibility into relevant clinical trials so oncologists can make better informed, more personalized care decisions for patients.

 

“With the implementation of this system, Miami Cancer Institute is among a small number of elite cancer programs across the globe to bring all aspects of precision medicine under one roof,” said Jeff Boyd, Ph.D., associate deputy director, translational research and genomic medicine at Miami Cancer Institute. “It’s exciting to have our in-house genetic experts work alongside the patient care team, expanding access to personalized genetic analysis and individualized medicine, to patients in South Florida, as well as the Caribbean and Latin America.”

 

Genomic testing continues to provide the deep insights needed to enable more targeted and personalized treatment to enhance care and lower costs. However, implementing a precision medicine program can be difficult due to challenges like interpreting an increasing amount of complex data and the inability to share and communicate information across departments. To help healthcare organizations keep pace with rapid developments in the field of genomics, Philips IntelliSpace Precision Medicine brings together genomic data alongside disease histology and patient phenotype for a complete biomarker-informed diagnostic and therapeutic picture of a patient, while also providing a seamless clinical workflow platform for care teams.

 

“At Miami Cancer Institute, we’re committed to a vision to support next generation sequencing to use genomic data to help find the most appropriate and efficient treatment options for our patients,” said Qi Wei, Ph.D., director, genomics laboratory service at Miami Cancer Institute. “By leveraging this solution from Philips, we can provide our oncology care teams with the information they need to make better care decisions, helping our institution deliver on our mission to provide the highest clinical quality possible.”

 

This new initiative with Philips and Miami Cancer Institute also helped accelerate the lab’s launch of the TruSight Tumor 170 (TST170) next-generation sequencing testing service, in collaboration with Illumina and N-of-One. TST170 is a test designed to cover hundreds of genes and variant types associated with common solid tumors. This allows multiple biomarkers to be evaluated from one sample, providing more efficient and quality interpretation of molecular tests in a cost-effective way. Philips IntelliSpace Precision Medicine Genomics will help with data capture and storage of variants, annotations, clinical interpretation and recommended treatments to support adherence and variant-based patient outcomes.

 

“With the healthcare landscape constantly evolving, especially in areas related to precision medicine, hospitals and health systems need comprehensive solutions to present complete patient information quickly and accurately,” said Louis Culot, General Manager, Oncology Informatics, Philips. “At Philips, we’re committed to partnering with leading cancer centers like Miami Cancer Institute at Baptist Health to bring the highest level of precision diagnosis to cancer treatment options to help improve clinical quality, and reduce costs to treat patients more effectively early in their cancer care journey.”

 

IntelliSpace Precision Medicine Genomics is powered by Philips HealthSuite, enabling health systems to make informed, secure and timely decisions, in the right place at the right time. The Philips HealthSuite digital platform is a cloud-based, open platform of services, capabilities and tools designed to inspire and enable the development of next generation connected health innovations.

Philips at HIMSS

For more information on Philips’ full portfolio of integrated smart systems, devices, software and services that will be spotlighted at the upcoming HIMSS Global Conference & Exhibition in Orlando, FL, Feb. 11-15, 2019, visit www.philips.com/himss and follow @PhilipsLiveFrom for #HIMSS19 updates throughout the event.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2017 sales of EUR 17.8 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Read MoreRead Less

About Miami Cancer Institute

Miami Cancer Institute is a next-generation cancer treatment destination known for its leading clinical care and research, compassionate patient experience and state-of-the-art technology – including the first proton therapy center in South Florida, Latin America and the Caribbean, and the only radiation oncology program in the world with each of the latest radiation therapies in one place. The Institute offers an impressive roster of established community oncologists and renowned cancer experts, clinical researchers and genomic scientists recruited from the nation’s top cancer centers. As Florida’s only member of the Memorial Sloan Kettering (MSK) Cancer Alliance, Miami Cancer Institute is part of a deep and functional collaboration that affords patients access to innovative treatments right here at home and ensures that the standards of care developed by our multidisciplinary disease management teams match those at MSK. Heralded nationally as one of the “hybrid” cancer centers of the future, Miami Cancer Institute combines high-quality community-based cancer care with the best of an academic cancer center, including innovative clinical trials tied to research and genomics and disease-specific surgeons, medical oncologists and radiation oncologists who are experts in their fields. For more information, visit MiamiCancerInstitute.com.

Read MoreRead Less

Topics

Contacts

Kathy O'Reilly

Kathy O'Reilly

Philips Group Press Office

Tel.: +1 978-221-8919

Georgi Pipkin

Baptist Health, Media Relations

Tel: +1-786-527-9524

Media assets

Miami Cancer Institute, part of Baptist Health South Florida, adopts Philips IntelliSpace Precision Medicine Genomics
Philips IntelliSpace Precision Medicine Genomics

Share on social media